General Information of Drug (ID: DMVDCGZ)

Drug Name
Pyridoxamine Drug Info
Synonyms Pyridorin (TN)
Indication
Disease Entry ICD 11 Status REF
Diabetic kidney disease GB61.Z Phase 3 [1]
Diabetic nephropathy GB61.Z Phase 3 [1]
Cross-matching ID
PubChem CID
1052
ChEBI ID
CHEBI:16410
CAS Number
CAS 85-87-0
TTD Drug ID
DMVDCGZ
INTEDE Drug ID
DR1911

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
Drug Status:
Investigative Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pyridoxine-5'-phosphate DMFUNL1 Discovery agent N.A. Investigative [5]
Drug Name Drug ID Indication ICD 11 Highest Status REF
PF-4494700 DMJ7IKW Alzheimer disease 8A20 Phase 3 [6]
Alagebrium chloride DMD741P Hypotension BA20-BA21 Phase 2/3 [7]
TTP-448 DMR37X8 Alzheimer disease 8A20 Phase 2 [6]
TTP-4000 DMCG01R Alzheimer disease 8A20 Phase 1 [8]
DBT-066 DMFYCQ1 Dementia 6D80-6D86 Investigative [9]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Advanced glycosylation end product receptor (AGER) TTMO9HF RAGE_HUMAN Inhibitor [2] , [3]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Pyridoxamine-phosphate oxidase (PNPO) Main DME DE3Z1RA PNPO_HUMAN Substrate [4]

References

1 ClinicalTrials.gov (NCT02156843) Pyridorin in Diabetic Nephropathy. U.S. National Institutes of Health.
2 Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin resistance in obese, type 2 diabetic mice. Protein Pept Lett. 2010 Sep;17(9):1177-81.
3 The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes. 2002 Sep;51(9):2826-32.
4 An LC-MS/MS-based method for the quantification of pyridox(am)ine 5'-phosphate oxidase activity in dried blood spots from patients with epilepsy. Anal Chem. 2017 Sep 5;89(17):8892-8900.
5 Pyridoxine 5'-phosphate oxidase is a novel therapeutic target and regulated by the TGF-beta signalling pathway in epithelial ovarian cancer. Cell Death Dis. 2017 Dec 13;8(12):3214.
6 Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease. Expert Opin Investig Drugs. 2015 Mar;24(3):393-9.
7 Effect of the age cross-link breaker alagebrium on anterior segment physiology, morphology, and ocular age and rage. Trans Am Ophthalmol Soc. 2009 Dec;107:146-58.
8 Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases. Future Neurol. 2009; 4(2): 167-177.
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2843).